Cardiovascular disease risk factor assessment and management in gout: An analysis using guideline-based electronic clinical decision support

New Zealand Medical Journal

Volumn 121, Issue 1285, 2008, Pages

  Colvine, Keith ^a   Kerr, Andrew J ^b   McLachlan, Andrew ^b   Gow, Peter ^b   Kumar, Sunil ^b   Ly, Jason ^b   Wiltshire, Chris ^c   Robinson, Elizabeth ^d   Dalbeth, Nicola ^b,d  

^a NORTH SHORE HOSPITAL   (New Zealand)

^b MIDDLEMORE HOSPITAL   (New Zealand)

^c Enigma Consulting   (New Zealand)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIGOUT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; URIC ACID; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPUTER PROGRAM; DECISION SUPPORT SYSTEM; DISEASE DURATION; FEMALE; GOUT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK MANAGEMENT; SCREENING; SYSTOLIC BLOOD PRESSURE; CLASSIFICATION; CLINICAL TRIAL; HYPERCHOLESTEROLEMIA; HYPERTENSION; METABOLIC SYNDROME X; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; ORGANIZATION AND MANAGEMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DECISION SUPPORT SYSTEMS, CLINICAL; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT;

EID: 56649112606     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Mikuls TR, Farrar JT, Bilker WB, et al. Gout epidemiology: Results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis. 2005;64(2):267-72.
2. Janssens HJ, van de Lisdonk EH, Bor H, et al. Gout, just a nasty event or a cardiovascular signal? A study from primary care. Fam Pract. 2003;20(4):413-6.
3. Abbott RD, Brand FN, Kannel WB, Castelli WP. Gout and coronary heart disease: The Framingham Study. J Clin Epidemiol. 1988;41(3):237-42.
4. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54(8):2688-2696.
5. Jackson R, Lawes CM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet. 2005;365(9457):434-41.
6. Law MR, Wald NJ. Risk factor thresholds: Their existence under scrutiny. BMJ. 2002;324(7353):1570-6.
7. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20(3):895-900.
8. Grundy SM, Brewer HB, Jr., Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/ American Heart Association conference on scientific issues related to definition. Circulation. 2004;109(3):433-8.
9. The New Zealand Guidelines Group. The assessment and management of cardiovascular risk and the guidelines for the management of type 2 diabetes. Wellington: NZGG; 2003. http://www.nzgg.org.nz/guidelines/ 0035/CVD_Risk_Full.pdf and http://www.nzgg.org.nz/guidelines/0036/ Diabetes_full_text.pdf
10. Jackson R. Updated New Zealand cardiovascular disease risk-benefit prediction guide. BMJ. 2000;320(7236):709-10.
11. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312-24.
12. Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: A population-based cohort study. Arthritis Rheum. 2005;52(2):402-11.
13. Han C, Robinson DW, Jr., Hackett MV, et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006;33(11):2167-72.
14. del Rincon ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44(12):2737-45.
15. Hall FC, Dalbeth N. Disease modification and cardiovascular risk reduction: Two sides of the same coin? Rheumatology (Oxford). 2005;44(12):1473-82.
16. Pham T, Gossec L, Constantin A, et al. Cardiovascular risk and rheumatoid arthritis: Clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine. 2006;73(4):379-87.
17. Klemp P, Stansfield SA, Castle B, Robertson MC. Gout is on the increase in New Zealand. Ann Rheum Dis. 1997;56(1):22-6.
18. Prior IA, Welby TJ, Ostbye T,et al. Migration and gout: The Tokelau Island migrant study. Br Med J (Clin Res Ed). 1987;295(6596):457-61.
19. Roddy E, Zhang W, Doherty M. Concordance of the management of chronic gout in a UK primary care population with the EULAR gout recommendations. Ann Rheum Dis 2007;66(10):1311-5.
20. Singh JA, Hodges JS, Toscano JP, Asch SM. Quality of care for gout in the US needs improvement. Arthritis Rheum. 2007;57(5):822-9.
21. Wilson PW, D'Agostino RB, Parise H, et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112(20):3066-72.
22. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: The Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109-15.
23. Grundy SM. Drug therapy of the metabolic syndrome: Minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov. 2006;5(4):295-309.
24. Dessein PH, Shipton EA, Stanwix AE, et al. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: A pilot study. Ann Rheum Dis. 2000;59(7):539-43.
25. Wurzner G, Gerster JC, Chiolero A, et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens. 2001;19(10):1855-60.
26. Lee HY, Kang HJ, Koo BK, et al. Clinic blood pressure responses to two amlodipine salt formulations, adipate and besylate, in adult Korean patients with mild to moderate hypertension: A multicenter, randomized, double-blind, parallel-group, 8-week comparison. Clin Ther. 2005;27(6):728-39.
27. Caspi D, Lubart E, Graff E, et al.The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum. 2000;43(1):103-8.
28. Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: A sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295(3):306-13.